Results from a retrospective cohort study from 2015 to 2020 demonstrated a notable rise with increasing age in pneumonia-related medical encounters following.
Ambrx Biopharma (NYSE:AMAM – Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Analyst Recommendations This is a summary of recent ratings […]
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) and Ambrx Biopharma (NYSE:AMAM – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability. Insider and Institutional Ownership 89.6% of BioCryst Pharmaceuticals shares […]
This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID Preliminary topline immune.
A recently published study by FMI expects the global needle-free injectors market to augment at a 12% CAGR from 2022 to 2032. By the end of the said assessment period, a valuation of US$ 42.79 Billion is expected for the market. Faster drug delivery is the key driver for the needle-free injector market. Increasing d.